The EGFR-RAS-ERK pathway plays a key role in cancer development and progression. However, the integral assembly of EGFR-RAS-ERK signaling complexes from the upstream component EGFR to the downstream component ERK is largely unknown. Here, we show that hematopoietic PBX-interacting protein (HPIP) interacts with all classical components of the EGFR-RAS-ERK pathway and forms at least two complexes with overlapping components. Experiments of HPIP knockout or knockdown and chemical inhibition of HPIP expression showed that HPIP is required for EGFR-RAS-ERK signaling complex formation, EGFR-RAS-ERK signaling activation, and EGFR-RAS-ERK signaling–mediated promotion of aerobic glycolysis as well as cancer cell growth in vitro and in vivo. HPIP expression is correlated with EGFR-RAS-ERK signaling activation and predicts worse clinical outcomes in patients with lung cancer. These results provide insights into EGFR-RAS-ERK signaling complex formation and EGFR-RAS-ERK signaling regulation and suggest that HPIP may be a promising therapeutic target for cancer with dysregulated EGFR-RAS-ERK signaling.
11 November 2026 in Science Translational Medicine
Human infections with mpox virus (MPXV) since 2022 have resulted in more than 188,000 cases reported globally as of June 2026, highlighting the urgent need for effective therapeutics. Here, we recruited smallpox vaccinees and donors with incidental vaccinia virus (VACV) exposure and isolated a panel of human anti-A33/A35 monoclonal antibodies (mAbs) from the latter using recombinant MPXV A35 as a cross-reactive bait. These mAbs recognized four distinct nonoverlapping epitopes (epitopes 1 to 4) and one composite epitope (epitope 3 + 4) on MPXV A35 and exhibited cross-reactivity against multiple orthopoxviruses (OPXVs). Cryo–electron microscopy structural analysis revealed that the high-affinity epitope 3 + 4 mAb HD15 engages an epitope at the A35 dimer interface that is conserved across OPXVs. Combinations of mAbs targeting nonoverlapping epitopes mediated synergistic, Fc-dependent neutralization in vitro; conferred therapeutic protection against lethal VACV challenge; and reduced viral burden and disease severity after MPXV challenge in mice. Together, these findings establish a single-antigen, multiepitope strategy for the development of broadly protective therapeutics against OPXVs.